Management of Subclinical Endometritis by Immunomodulators and Proteolytic Enzymes
No Thumbnail Available
Date
2023-09
Journal Title
Journal ISSN
Volume Title
Publisher
The Association of Mastitis
Abstract
Five hundred repeat breeder cows (2-4 parity) were randomly selected from livestock farm, Kuthuliya and villages of Rewa (M.P.). On the basis of endometrial cytology by cytobrush technique 140 repeat breeder cows (28%) were diagnosed to be suffering from subclinical endometritis. Out of the animals found positive 30 cows were selected and were divided into 5 groups (n=06 per group). The group wise treatment allotted were Group I- Levamisole, 2.5 mg/kg body weight, once for three weeks, S/c; Group II- 100 ?gm E. coli LPS in 30 ml PBS, single I/U infusion; Group III- 500 mg Benzathine cephapirin, single I/U infusion; Group IV- Proteolytic enzymes in 10 ml distilled water, single I/U infusion and Group V (Control)-no treatment. All the animals were subjected to endometrial cytology at 12 hrs., 24 hrs. and 48 hrs. post-treatment. The animals were bred at next successive oestrus and pregnancy was confirmed 60 days post insemination. Endometrial cytology in treatment group I revealed that the PMN per cent increased significantly (p<0.05) from 0 hrs. to 24 hrs. In groups II, III and IV, the increase in PMN per cent was significant (p<0.05) from 0 hrs. to 48 hrs. The overall pregnancy rate was higher (83.33%) in treatment groups II and IV as compared to treatment group III (50.00%), group I (33.33%) and group V (0.00%), respectively. It was concluded that immunomodulators like E. coli lipopolysaccharide and proteolytic enzymes proved to be better for enhancing uterine immunity and pregnancy rates in subclinical endometritic repeat breeder cows.
Description
Keywords
Subclinical endometritis, endometrial cytology, immunomodulators, proteolytic enzymes
Citation
Manjhi V.K., Bajaj N.K., Shukla S.P., Kaurav P.S.. Management of Subclinical Endometritis by Immunomodulators and Proteolytic Enzymes. Journal of Animal Research. 2023 Sep; 13(5): 703-708